Back to results
US 2026/0229307 A1Published application
Cleaved neoepitopes
AssigneeIogenetics, LLC
InventorsJane Homan, Robert D. Bremel
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating, by administration of a cathepsin inhibitor, a subject who is affected by a tumor comprising a specific tumor mutation in a peptide that is cleaved with high frequency by a cathepsin and in which such cleavage prevents the presentation of a neoantigen thereby enabling immune evasion and tumor progression.
Claims59
A method of treating a subject having a tumor comprising:
- Performing or having performed an assay to identify tumor mutations on a nucleic acid sample from the subject to determine if a mutation of a protein encoded by a Ras gene is present;
- and
- If the subject has a mutation of a protein encoded by a Ras gene, administering a cathepsin inhibitor to the subject.
A method of treating a subject having cancer comprising:
- Performing or having performed an assay to identify tumor mutations in a nucleic acid sample from the subject to identify amino acid mutations in tumor proteins in comparison to corresponding wild-type sequences of the protein in the subject or in a reference human subject;
- Identifying 9mer amino acid peptides which comprise the identified amino acid mutations in the tumor proteins;
- Determining the probability of cleavage by a cathepsin of each octomer centered on a potential scissile bond within any 9mer peptide that comprises an identified amino acid mutation in the tumor proteins;
- Identifying the mutated tumor proteins which have a probability of cathepsin cleavage within such octomers that exceeds a predetermined score;
- and
- If the subject has one or more mutated tumor proteins for which the cathepsin cleavage score for peptides comprising the mutant exceeds the predetermined score, treating the subject with a cathepsin inhibitor.
3 more elements
Dependencies are inferred from the claim text.